Compare NMRA & EOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NMRA | EOT |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Investment Bankers/Brokers/Service |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 424.4M | 265.6M |
| IPO Year | 2023 | N/A |
| Metric | NMRA | EOT |
|---|---|---|
| Price | $2.23 | $16.58 |
| Analyst Decision | Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 38.7K |
| Earning Date | 11-06-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.51% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $14.63 |
| 52 Week High | $11.57 | $18.30 |
| Indicator | NMRA | EOT |
|---|---|---|
| Relative Strength Index (RSI) | 44.31 | 41.47 |
| Support Level | $2.13 | $16.45 |
| Resistance Level | $2.36 | $16.86 |
| Average True Range (ATR) | 0.19 | 0.23 |
| MACD | -0.04 | -0.04 |
| Stochastic Oscillator | 16.67 | 22.83 |
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
Eaton Vance National Municipal Opportunities Trust is a diversified, closed-end management investment company. The company's investment objective is to provide current income exempt from regular federal income tax and to achieve capital appreciation. The company invests a majority of its assets in debt obligations issued by or on behalf of states, territories, and possessions of the United States, including the District of Columbia, and their political subdivisions, agencies, or instrumentalities, the interest on which is exempt from regular federal income tax.